Figure S1. Related to Figure 1. (A)
Model for the hypothesis that eIF5B was conserved throughout the evolution of aerobic eukaryotes for hypoxic adaptation and metabolism. IF2/eIF5B likely evolved in the last universal common ancestor under anaerobic conditions, and contemporary bacterial and archaeal IF2 homologs are capable of performing protein synthesis during oxygen deficiency. (B) Validation of siRNAmediated eIF5B knockdown success by immunoblot for Figure 1D . Representative immunoblots are shown. (C) Area under curve measurements of ribosome density profiles of normoxic and hypoxic U87MG treated with control non-silencing (NS) or eIF5B-specific siRNA ( Figure 1D ). (D) Representative immunoblots of normoxic and hypoxic MCF7 and A549 treated with NS or eIF5B-specific siRNA. Normoxic and hypoxic U87MG treated with control non-silencing (NS) or eIF5B-specific siRNA were subjected to ribosome density fractionation, followed by RT-qPCR measurements of elongator tRNA Arg levels in free, 40S/43S, and 60S/80S fractions. (C) Representative control immunoblots for Figure 2D . (D) Normoxic and hypoxic U87MG treated with control non-silencing (NS) or eIF5B-specific siRNA were subjected to ribosome density fractionation, followed by RT-qPCR measurements of NDRG1 and ATF4 steady-state mRNA levels (based on aggregate abundance across all fractions). (E) Representative immunoblots of U87MG exposed to 4 hr of heat shock (43 0 C) versus untreated controls ( ACTB  ADCY8 GNAS MAPK7  RALB  GJA1  PRKD2 PRKG1 GNAI2 ROCK2   TUBA4A ROCK1 TUBB6 TUBB2A ACTG1 TUBB3  SIPA1  CD44   EPN2  RAB5C EPS15  CLTB  VPS29  PSD3  RABB35  WIPF1 CHMP2B RAB11A   VTN1  AP2A2  SEC22B  CHMP5  RABEP1  CHMP4B  STAM  RIP11 Figure S4 . Related to Figure 4. (A, B, top panel) KEGG pathway enrichment analysis of eIF5B-dependent cellular systems. (B, bottom panel) Hexagon models are shown, depicting TE, steady-state RNA level, protein output, and steady-state protein level for each individual detected protein involved in amino acid synthesis and protein processing, cell adhesion, and endocytosis. Legend is shown in Figure 4B . DTT was added to reduce cysteines at a final concentration of 10 mM. Cysteines were reduced at 60°C for 1 hour.
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Sample was cooled to room temperature and iodoacetamide was added to a final volume of 20 mM. Samples were incubated at room temperature in the dark for 30 min. Samples were then acetone precipitated overnight, and protein precipitates were centrifuged at 23,000 g for 15 min. Precipitates were re-suspended in 50 uL of NH 4 HCO 3 (pH 8.3), and MS grade Trypsin/LysC (Promega) was added to a final protease:protein ratio of 1:50 and samples were digested overnight at 37 0 C. Samples were lyophilized and re-suspended in 0.1% trifluoroacetic acid (TFA).
Peptides were fractionated using the Pierce High pH Reverse Phase Peptide Fractionation Kit (Pierce), following the manufacturer's instructions. Each sample was fractionated into 8 high pH fractions.
Fractionated peptides were lyophilized, and lyophilized peptide mixtures were dissolved in 0.1% formic acid and loaded onto a 75 µm x 2 cm PepMap 100 Easy-Spray pre-column filled with 3 µm C18 beads (Thermo Fisher Scientific) followed by an in-line 75 µm x 50 cm PepMap RSLC EASY-Spray column filled with 2 µm C18 beads (Thermo Fisher Scientific) at a pressure of 700 BAR. Peptides were eluted over 120 to 240 min at a rate of 250 nl/min using a 0 to 35% acetonitrile gradient in 0.1 % formic acid. For ribosome density fractionated samples, "free" fractions were eluted over 120 min each, while "40/60/80S" and "polysome" fractions were eluted over 180 each.
eIF5B-depleted and control samples were eluted over 240 min each. Peptides were introduced by nanoelectrospray into an LTQ-Orbitrap Elite hybrid mass spectrometer (Thermo-Fisher) outfitted with a nanospray source and EASYnLC split-free nano-LC system (Thermo Fisher Scientific). The instrument method consisted of one MS full scan (400-1500 m/z) in the Orbitrap mass analyzer, an automatic gain control target of 1e6 with a maximum ion injection of 200 ms, one microscan, and a resolution of 240,000. Ten data-dependent MS/MS scans were performed in the linear ion trap using the ten most intense ions at a normalized collision energy of 35. The MS and MS/MS scans were obtained in parallel fashion. In MS/MS mode automatic gain control targets were 1e5 with a maximum ion injection time of 50 ms. A minimum ion intensity of 5000 was required to trigger an MS/MS spectrum. Dynamic exclusion was applied using a maximum exclusion list of 500 with one repeat count with a repeat duration of 30 s and exclusion duration of 15 s.
Raw MS files acquired from the mass spectrometer were processed using PEAKS software (Bioinformatics Solutions Inc.). Data was loaded into the software program and data from each fraction was refined to merge scans within 2 min and 10.0 ppm. Spectra with PEAKS filter scores <0.5 were excluded. De novo sequencing and database searching was done using a precursor mass cutoff of 10.0 ppm and a fragment mass tolerance of 0.6 Da.
Carbidomethylation of cysteine (+57.02 Da) residues was selected as a fixed modification while variable modifications included 13 C 6 -15 N 2 SILAC on K (8.01Da), 13 C 6 -15 N 4 SILAC on R (10.02), Oxidation of M (15.99).
Label-free quantification was performed in PEAKS using SILAC labels. Data sets are available at the PRoteomics IDEntifications (PRIDE) database via ProteomeXchange, accession PXD006799.
RNA interference. Small interfering RNA (siRNA) pools (siGENOME siRNA, GE Dharmacon) were transfected at a final concentration of 50 nM using Effectene (Qiagen) for 48 hr.
Cell viability assays. Fluorescein diacetate (FDA) staining was used to assess cell viability. Briefly, cells were incubated in FDA (10 µg/ml) for 30 min at 37 0 C with DAPI counterstaining, and visualized with fluorescence microscopy (excitation and emission wavelengths of 492 nm and 517 nm, respectively) after washing with PBS. In addition, cell viability measurements were performed using the RealTime-Glo MT Cell Viability Assay (Promega) at indicated time points over 48 hr on cells grown in the same well.
Global protein synthesis measurements. Global protein synthesis was measured by puromycin (Thermo Fisher Scientific) incorporation (1 µg/ml) for 20 min, followed by immunoblot analysis with an anti-puromycin antibody (see below).
Immunoblot. Immunoblots were performed using standard techniques using the following antibodies: β-actin RNA-sequencing and analysis. Equal volumes of relevant ribosome density fractionated fractions were combined to yield the "free", "40/60/80S", and "polysome" samples, respectively. Poly(A) RNA selection, library preparation, and RNA sequencing were performed by the Sylvester Comprehensive Cancer Center Oncogenomics Core Facility, using the KAPA Stranded mRNA-Seq Kit (KAPA Biosystems) and NextSeq 500 High Output Kit v2 (Illumina).
Paired-end (2 x 75 bp) sequencing runs at a depth of >50 million reads were performed on the libraries using the NextSeq 500 system (Illumina).
Raw data pre-processing was performed by the Sylvester Comprehensive Cancer Center Biostatistics and Bioinformatics Core Facility. For differential expression analysis, raw paired-end read data in FASTQ format were assessed for quality with FastQC (v. 11.5, Babraham Bioinformatics) . Trimmomatic (Bolger et al., 2014) (v. 0.32) was used to remove adapters, Illumina-platform specific sequences, and low quality leading and trailing bases.
